Neola Medical

Hem
Sverige
Lund
Neola Medical

Our vision is to give preterm born infants a better start in life by continuous lung monitoring

Neola Medical AB (publ) has the potential to revolutionize neonatal care with Neola, a medical technology product that offers continuous lung monitoring and real-time alerts of life-threatening complications using a cutting-edge technology that measures lung volume and oxygen gas concentration. Neola has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants. Founded in 2016 and headquartered in Lund, Sweden, Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care.

05/02/2026

📣 We hereby invite you to a live presentation of our Q4 report of 2025!

The Q4 report of 2025 will be presented by CEO Hanna Sjöström and CFO David Folkesson online hosted by Investor Studios. Following the presentation, there will be a Q&A, where viewers have the opportunity to ask questions directly in the live chat.

🗓️ February 12, 2026, at 11:00 CET (11.00)
🎥 Watch the presentation here: https://youtube.com/live/-_0FXFp8uXM

💡Read more in the press release here: https://neolamedical.com/mfn_news/neola-medical-invites-to-presentation-of-the-q4-report-2025/

17/12/2025

📣 Today we released the winter edition of Neola Medical’s Investor Letter 2025

“2025 has been a year of important clinical and organizational progress for Neola Medical. With a solid technological and intellectual property foundation, we continue to move forward in both our clinical development and organizational growth,” says CEO Hanna Sjöström

💡 Read the entire press release and the investor letter here: https://neolamedical.com/mfn_news/neola-medicals-ceo-shares-recent-company-highlights-in-winter-2025-investor-letter/

15/12/2025

Study visit at Stanford NICU 👶🇺🇸

Last week Neola Medical had the opportunity to visit the Neonatal Intensive Care Unit (NICU) at Stanford Medicine Children's Health in Palo Alto — widely recognized as a global reference center for neonatal care in the U.S.

We were pleased to meet with Dr. Valerie Chock and Impact1 co-director Janene Fuerch and gain valuable insights into daily clinical practice in the NICU.

A sincere thank you to the Stanford team for the warm welcome and for your extraordinary commitment to the most vulnerable patients 🌟

💡 Learn more about the NICU here: www.stanfordchildrens.org

09/12/2025

📣 Neola Medical expands leadership team with appointment of Director Disposable Product Development

“Strengthening our leadership team with experience in scaling advanced disposables is of outmost strategic importance for Neola Medical as our disposables are a key driver for future recurring revenue streams. Charlotta Lagerblad brings deep experience in taking advanced disposable products from innovation into large scale manufacturing and global sales,” says CEO Hanna Sjöström.

💡 Read more in the press release here: https://neolamedical.com/mfn_news/neola-medical-expands-leadership-team-with-appointment-of-director-disposable-product-development/

04/12/2025

🚀 Explore our new website! 🚀

We’ve launched a new version of our website to make it easier to follow our progress, learn about our technology, and access investor information. We hope you will appreciate the new design and improved navigation, developed to give shareholders and partners an even clearer overview of our journey.

“Our updated website mirrors Neola Medical’s continued progress and growing presence in both Sweden and the U.S. I invite all our shareholders and partners to visit and explore it,” says CEO Hanna Sjöström

🔗 Visit our website at www.neolamedical.com ✨

02/12/2025

📣 Neola Medical granted U.S. patent for disposable probes, strengthening future revenue model in target market 🇺🇸

“These disposables are central to our future business model, where recurring revenues from daily probe replacements are expected to provide significant leverage. Securing patent protection in the U.S. strengthens our competitive position in our most important target market and protects our unique optical design,” says CEO Hanna Sjöström

💡 Read more in the press release here: https://neolamedical.com/mfn_news/neola-medical-granted-u-s-patent-for-disposable-probes-strengthening-future-revenue-model-in-target-market/

26/11/2025

🌟 Visiting the U.S. Study Site 🇺🇸

Neola Medical recently visited the Neonatal Intensive Care Unit (NICU) at Children’s Regional Hospital at Cooper University Health Care in Camden, New Jersey — first study site for our planned clinical study on preterm born babies in the U.S. 🫁

We were grateful to meet Professor Vineet Bhandari, Principal Investigator and Division Head of Neonatology, and to receive valuable insight into the clinical environment. 🌟

A warm thank you to the Cooper team for welcoming us and for the important work you do every day for the most vulnerable patients. 👶

💡 Learn more about Children’s Regional Hospital at Cooper here: www.cooperhealth.org

13/11/2025

📣 Neola Medical granted Patent in China for reducing optical noise in lung monitoring measurements

“This Chinese patent expands our IP protection within a new patent family and strengthens our international position. The invention contributes to optimizing the Neola® system for continuous lung monitoring, helping to support consistent measurement quality,” says CEO Hanna Sjöström

About the patent
The granted patent belongs to Neola Medical’s patent family “A device for smoothing spectral transmission modulations and a method thereof” and protects the company’s innovation for optimizing measurement data by reducing interference in the optical fiber during lung monitoring.

💡 Read more in the press release here: https://www.neolamedical.com/mfn_news/neola-medical-granted-patent-in-china-for-reducing-optical-noise-in-lung-monitoring-measurements/

16/10/2025

📣 Neola Medical Strengthens Global IP Portfolio with New Patents Granted in both the U.S. and China for Medical Device Neola®

“Patent protection in both the U.S. and China secures a key part of our medical device in two of the world’s most significant healthcare markets. It supports our pathway toward U.S. market authorization and long-term global commercialization,” says CEO Hanna Sjöström.

💡 Read more in the press release here: https://www.neolamedical.com/mfn_news/neola-medical-strengthens-global-ip-portfolio-with-new-patents-granted-in-both-the-u-s-and-china-for-medical-device-neola/

01/10/2025

📣 Today we released the autumn edition of Neola Medical’s Investor Letter 2025

“Strengthening our leadership team, expanding our patent portfolio, and deepening our international network through Stanford Impact1 are all important steps as we advance toward market authorization and continue our mission to improve outcomes for preterm born babies,” says CEO Hanna Sjöström.

💡 Read the entire press release and the investor letter here: https://www.neolamedical.com/mfn_news/neola-medicals-ceo-highlights-recent-progress-in-autumn-2025-investor-letter/

25/09/2025

📣 Neola Medical strengthens leadership team with appointment of Clinical Director

“We are very pleased to welcome Eva Bondesson to Neola Medical’s leadership team. Her extensive experience in global clinical development, including collaboration with the U.S. FDA and other regulatory authorities, will be highly valuable as we advance through the clinical phase and prepare for our planned U.S. market authorization. With her strong expertise in lung physiology and proven track record in leading international studies, she brings an important complement to our team and to our mission of improving outcomes for preterm born babies,” says CEO Hanna Sjöström.

💡 Read more in the press release here: https://www.neolamedical.com/mfn_news/neola-medical-strengthens-leadership-team-with-appointment-of-clinical-director/

16/09/2025

🚀 CEO Hanna Sjöström invited as panelist at Stanford Impact1 CEO Summit in Austin, Texas 🇺🇸

“It is an honor to return to the Stanford Impact1 CEO Summit and to contribute to the important dialogue around board and investor relationships. As a Stanford Impact1 company, Neola Medical benefits greatly from the expertise and networks that this unique program provides. The exclusive CEO Summit is an invaluable forum to share our journey, connect with thought-leaders, and exchange perspectives on how to bring impactful innovations like Neola® to pediatric patients worldwide,” says CEO Hanna Sjöström.

💡Learn more and read the entire article about the exclusive particiapation at Stanford Impact1 here: https://www.neolamedical.com/mfn_news/ceo-hanna-sjostrom-invited-as-panelist-at-stanford-impact1-ceo-summit-in-austin-texas/

💡Read the press release about the Stanford Impact1 program announcement in 2023 here: https://www.neolamedical.com/mfn_news/stanford-utser-neola-medicals-medicintekniska-produkt-till-en-viktig-innovation-for-neonatalvarden-och-ger-bolaget-stod-till-marknadsetablering-genom-exklusiva-programmet-impact1/

🎥 Watch the welcome speech to the Stanford Impact1 program in 2023 by founding director, James Wall, here: https://www.linkedin.com/feed/update/urn:li:activity:7119952940315926529

Adress

Scheelevägen 27
Lund
22363

Webbplats

https://www.neolamedical.com/

Aviseringar

Var den första att veta och låt oss skicka ett mail när Neola Medical postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Praktiken

Skicka ett meddelande till Neola Medical:

Genvägar

Vill du placera din praktik längst upp i Klinik-listan i Lund?

Dela

Typ

Medicin och hälsa